hyperthyroidism l-carnitine l carnitine for hyper thyroid and subclinical Metabolic Functional Cross Talk Between the and Liver L-Carnitine, Selenium & Thyroid Health l carnitine for subclinical hyperthyroidism – how much l-carnitine for hyperthyroidism

Magnetizing Hydrogel Nano-Particles: Towards The Automatization of a Tuberculosis Antigen Test

This work was supported by the Loterie Romande and the Fonds pour la Recherche en Sant du Qubec (SL)

Energizes skin cells and reduces signs of aging

discontinued CJC-1295 (DAC) Not FDA-approved Feature Phase III Trial Data Tesamorelin Yes (n=816 pooled) Sermorelin No adult Phase III VAT datasets CJC-1295 (DAC) No Feature Visceral Fat Reduction Tesamorelin 15-20% at 26 weeks Sermorelin Not formally studied in RCTs CJC-1295 (DAC) Not formally studied in RCTs Feature Liver Fat Reduction Tesamorelin 32% at 12 months (NAFLD trial) Sermorelin Not studied CJC-1295 (DAC) Not studied Feature Typical Research Dose Tesamorelin 2 mg daily Sermorelin 200-300 mcg nightly CJC-1295 (DAC) 1-2 mg weekly Feature Unique Advantage Tesamorelin Only FDA-approved GHRH with deepest trial evidence Sermorelin Longest historical track record CJC-1295 (DAC) Weekly dosing convenience Tesamorelin is the only GHRH peptide with active FDA approval and validated Phase III visceral-fat data

Cancer 19 , 625637 (2019)